0
Clinical Investigations: PULMONARY HYPERTENSION |

Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension*

Jean-Luc Vachiéry, MD; Nicholas Hill, MD, FCCP; Diane Zwicke, MD, FCCP; Robyn Barst, MD; Shelmer Blackburn, MD; Robert Naeije, MD
Author and Funding Information

*From the Departments of Cardiology (Dr. Vachiéry) and Pathophysiology (Dr. Naeije), Erasme University Hospital, Brussels, Belgium; Rhode Island Hospital (Dr. Hill), Providence, RI; St Luke’s Medical Center (Dr. Zwicke), Milwaukee, WI; the Department of Pediatrics (Dr. Barst), Columbia Presbyterian Medical Center, New York, NY; and United Therapeutics Corporation (Dr. Blackburn), Research Triangle Park, NC.

Correspondence to: Robert Naeije, MD, Laboratory of Physiology, Erasmus Campus, CP 604, Route de Lennik 808, B-1070 Brussels, Belgium; e-mail: rnaeije@ulb.ac.be



Chest. 2002;121(5):1561-1565. doi:10.1378/chest.121.5.1561
Text Size: A A A
Published online

Objective: Continuous IV epoprostenol (prostacyclin) therapy improves survival and quality of life in patients with pulmonary arterial hypertension (PAH). IV epoprostenol therapy may be limited by serious complications related to the need for an implanted central venous catheter, and its chemical instability and short half-life. Treprostinil is a longer-acting prostacyclin analog, chemically stable, and suitable for continuous subcutaneous administration. We report successful transitioning to subcutaneous treprostinil of patients who presented with life-threatening complications of IV epoprostenol delivery.

Design: Open, uncontrolled study.

Setting: ICUs and departments of cardiology at academic hospitals.

Patients: Eight patients with PAH treated with continuous IV epoprostenol.

Intervention: Transition to subcutaneous treprostinil following an empiric protocol.

Results: Transition to treprostinil was achieved successfully in 21 to 96 h, with no major adverse side effects, and no change in the improved clinical status achieved with IV epoprostenol. Doses of epoprostenol before transition ranged from 3.5 to 75 ng/kg/min (mean, 27 ng/kg/min). Doses of treprostinil at completion of the transition ranged from 3 to 65 ng/kg/min (mean, 22 ng/kg/min). Four to 11 months later, the patients remained clinically improved. In spite of mild-to-moderate infusion site pain, all patients reported an improved sense of comfort and well-being.

Conclusion: Patients with PAH can be safely transitioned from treatment with IV epoprostenol to subcutaneous treprostinil.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543